(PHAT) – Globe Newswire
-
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
-
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024
-
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients
-
Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
-
Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital
-
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD
-
Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn
-
Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates
-
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults
-
Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicill
-
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD
-
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application
-
Phathom Pharmaceuticals Reports Second Quarter 2023 Results
-
Bragar Eagel & Squire, P.C. Is Investigating Integra, Chinook, Phathom, and Akumin and Encourages Investors to Contact the Firm
-
Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD
-
Phathom Pharmaceuticals Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
-
Bragar Eagel & Squire, P.C. Is Investigating Phathom, Reata, and Comerica and Encourages Investors to Contact the Firm
-
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
-
PHATHOM ALERT: Bragar Eagel & Squire, P.C. is Investigating Phathom Pharmaceuticals, Inc. on Behalf of Phathom Stockholders and Encourages Investors to Contact the Firm
-
Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock
-
Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA
-
Phathom Pharmaceuticals Reports First Quarter 2023 Results
-
Phathom Pharmaceuticals Presents New Data at Digestive Disease Week® (DDW) 2023
-
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Phathom Pharmaceuticals Announces Regulatory Update and Plans for 2023 Erosive Esophagitis and H. pylori Commercial Launch
-
Phathom Pharmaceuticals Announces Regulatory Update and Plans for 2023 Erosive Esophagitis and H. pylori Commercial Launch
-
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
-
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
-
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
-
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
-
Phathom Pharmaceuticals Provides Regulatory Updates
-
Phathom Pharmaceuticals Provides Regulatory Updates
-
TOP RANKED ROSEN LAW FIRM Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
-
Bragar Eagel & Squire, P.C. Is Investigating Credit Acceptance, and Phathom and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Is Investigating Phathom, Super Micro, and Fate and Encourages Investors to Contact the Firm
-
PHATHOM ALERT: Bragar Eagel & Squire, P.C. is Investigating Phathom Pharmaceuticals, Inc. on Behalf of Phathom Stockholders and Encourages Investors to Contact the Firm
-
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
-
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
-
Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis
-
Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis
-
Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates
-
Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates
-
Phathom Pharmaceuticals to Participate in Upcoming Investor Healthcare Conferences
-
Phathom Pharmaceuticals to Participate in Upcoming Investor Healthcare Conferences
-
Phathom Pharmaceuticals Announces Placement of the Remaining $40 Million in Non-Dilutive Capital under its up to $300 Million Revenue Interest Financing Agreement
Back to PHAT Stock Lookup